Nicolas A. Bamat, MD MSCE

Day 1 on our annual symposium! From BPD-prematurity is a life long disease! to Developmental care; PH and inhaled meds! @neo_twiter @EBNEO @NeoConsortium @nbamat @nicupodcast

As of today 240! Incredible growth, 104 for dinner, 31 posters! @EBNEO @neo_twiter @NeoConsortium @nicupodcast @What_Baker_Said @nbamat @kaashif_ahmad @MilenkaCuevas

@EBNEO Let’s submit the votes for the most impactful publication! #neoEBM

Select the finalists for the 2023 @EBNeo Impact Article of the Year! 👇 buff.ly/3R5JhMy Which of these 8 great publication will have the most impact on neonatal care? #EBNeoImpact23 #neoebm #neoTwitter

Introducing the #EBNeoImpact23 nominees! This UCM vs DCC trial was published in Pediatrics - buff.ly/41Lqn36 - and disseminated via #ebneoalerts on 11/11/23. Did it impact your neonatal practice? Share your experience with the #neoebm and #neoTwitter community!

Introducing the #EBNeoImpact23 nominees! The IMPACT trial was published in Pediatrics - buff.ly/41NUUh2 - & disseminated via #ebneoalerts on 8/12/23. Open access #ebneoreviews: buff.ly/48JVNrl Did it impact your practice? Share your experience!

Sharing our new paper led by @Dr_Rasheda with @BrianKingNeo @Dr_KSGautham & @souvik_neo (from workshop in #PAS2023) Navigating Information Overload on Social Media: Opportunities and Misadventures for Clinicians and Professionals newbornjournal.org/abstractArticl… #neoEBM @EBNEO @ESPR_ESN

@EBNEO @NEJM Looks like the CDC is recommending either Abrysvo or Beyfortus, but not both: cdc.gov/vaccines/vpd/r… We are certainly administering Beyfortus, but can't say we are routinely asking mothers if they received Abrysvo...

@EBNEO @NEJM Anecdotally, it feels like we are seeing less RSV this year. Are there data to support this? Would be interesting to hear from our OBGYN colleagues what the uptake for Abrysvo has been among expectant mothers. The introduction of Beyfortus also complicates measuring its impact.

Introducing the #EBNeoImpact23 nominees! The MATISSE trial was published in @NEJM buff.ly/418aHni - and disseminated via #ebneoalerts on 5/13/23. Did it impact your neonatal practice? Share your experience with the #neoebm and #neoTwitter community!

@BrianKingNeo @EBNEO @NEJM 👍👍 Particularly if they are costly and/or risk unnecessary treatment or intervention... Beware the cascade...

@EBNEO @NEJM Were any centers routinely using NIRS during the first few days of life among extremely preterm infants when this was conducted? Did any centers stop after it was published? Device trials are rare, but important. We can't simply assume more devices are better.

Introducing the #EBNeoImpact23 nominees! The SafeBoosC-III trial was published in @NEJM - buff.ly/3UWNW3E - and disseminated via #ebneoalerts on 4/22/23. Did it impact your neonatal practice? Share your experience with the #neoebm and #neoTwitter community!

@EBNEO @NEJM We hadn't adopted cerebral NIRS prior to this trial. I am assuming some centers had? Would love to hear from providers in centers that were using it, and to know if this trial impacted their practice. Deimplementation can be even trickier than implementation!

It's time for the 5th @EBNEO Impact Article of the Year campaign! We'll close 2024 by reviewing #neoebm highlights from 2023. A year from dissemination, have these pubs impacted your neonatal care? ✅ Consider the 8 nominees by following the links: buff.ly/3R5JhMy 1/2

✅ Follow posts of their initial #ebneoalerts and #ebneoreviews in the coming days ✅ Vote for the 2 finalists & choose the most impactful article on ebneo.org on 12/29 and 12/31 ✅ Tune in to a campaign wrap-up with @nicupodcast in early 2025 #EBNeoImpact23 2/2

#neotwitter What do you think are the major controversies in the field of bronchopulmonary dysplasia? If you've worked at multiple locations, what are the major practice variations and what causes most disagreement in this field?

@BrianKingNeo @drbretty @ambaln A couple of slides from my 2024 PAS presentation on this topic.

@drbretty @ambaln @nbamat Definitely a topic here in the US. Seems to be two schools of thought - Tracheostomy and discharge, maybe ~44 weeks PMA, or long haul NICU stay.

Our buddy @nbamat from @ebneo joins us to discuss polypharmacy and Furosemide use in the #nicu at @hottopicsneo! Keep an eye out for the EBNEO Article of the year!! #neotwitter buff.ly/49zFCht

@drbretty @MercyPerinatal @UniMelbMDHS @thewomens Congrats Brett!

Life news: I’m excited to be moving to the Mercy Hospital for Women @MercyPerinatal as the inaugural Professor/Director of Newborn Research @UniMelbMDHS I will miss the babies, families and my wonderful colleagues @thewomens, but can’t wait for this new challenge! #neotwitter

@Olesya_oz Thank you!

@nbamat Maybe it helps. "Each formulary has its own workflow, monograph template and style, and update routine. Focus on certain aspects of DI also varies, as well as the type of initiative and funding." doi.org/10.3390/childr…

To determine dosing of common medications in preterm infants, I rely on ___________ for guidance. Please RT 🙏 #neotwitter #neoebm